Tradestie Institutional Equity Comparison Engine
FDMT vs CGEM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CGEM Overall Edge
CGEM Captures Institutional Edge (4โ0 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cullinan Therapeutics, Inc. Common Stock (CGEM) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, FDMT trades at N/M Forward P/E with -222.7% operating margin (+4505.6% YoY revenue) versus CGEM at 6.7x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro) against CGEM sits in UNCLASSIFIED (9th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CGEM
FDMT N/M vs CGEM 6.7x Fwd P/E
Growth & Margin Winner
CGEM
Op Margin -222.7% vs 0.0% ยท YoY +4505.6% vs +0.0%
Momentum & Technical Winner
CGEM
1Y +13.3% vs +17.5% ยท 52W Pos 47% vs 12%
Options & Structure Winner
CGEM
BREAKDOWN (10th %ile IV) vs UNCLASSIFIED (9th %ile IV)
FDMT
NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap
$669.3M
1M Return
-4.04%
1Y Return
+13.33%
Forward P/E
N/M
Unified AI Score
42.1 / 100
HOLD
Tech 21.0
Fund 54.0
Flow 66.0
Mom 54.0
CGEM
NASDAQ
Cullinan Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.72
-5.45% 1D
Market Cap
$653.8M
1M Return
-24.83%
1Y Return
+17.53%
Forward P/E
6.7x
Unified AI Score
48.4 / 100
HOLD
Tech 45.0
Fund 51.0
Flow 50.0
Mom 59.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
FDMT +13.33%
CGEM +17.53%
Spread: +4.2 pp (CGEM Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
FDMT TTM Op. Margin: -222.7%
CGEM TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FDMT vs CGEM. Trailing 12-month operating profitability (FDMT -222.7% vs CGEM 0.0%) and valuation multiples (FDMT N/M vs CGEM 6.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | FDMT | CGEM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $669.3M | $653.8M | Larger Scale | FDMT |
| Trailing P/E Ratio Valuation | N/M | 6.7x | Lower Multiple | CGEM |
| Forward P/E Ratio Valuation | N/M | 6.7x | Lower Multiple | CGEM |
| Revenue Growth (YoY) Growth | +4505.6% | +0.0% | Higher Growth | FDMT |
| Operating Margin (TTM) Profitability | -222.7% | 0.0% | Higher Margin | CGEM |
| Net Profit Margin Profitability | -208.6% | 0.0% | Higher Margin | CGEM |
| Return on Equity (ROE) Capital Efficiency | -56.7% | -50.3% | Higher ROE | CGEM |
| 52-Week Range Position Momentum | 47% ($7โ$17) | 12% ($8โ$23) | Stronger Trend | FDMT |
| Beta / 30D Volatility Risk Regime | 1.89ฮฒ ยท 90% Vol | 1.56ฮฒ ยท 104% Vol | Lower Realized Risk | FDMT |
| Unified Institutional Score Composite Signal | 42.1 / 100 (HOLD) | 48.4 / 100 (HOLD) | Higher Composite | CGEM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full FDMT vs CGEM Buy Guide
FDMT
BREAKDOWN
62d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
10th %ile
IV Regime
Compressed (<25th %ile)
CGEM
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
9th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither FDMT nor CGEM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.